Key Takeaways
- Enrollment in the new Medicare Prescription Payment Plan did not meet expectations during its first two months.
In the first two months of the new Medicare Prescription Payment Plan (M3P), a mere 0.4% of Medicare Part D...
Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan
Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.
More from Medicare
• By
CMS Administrator Mehmet Oz said PBMs may deserve "one last chance" to fix the rebate system before federal regulations and legislation are enacted.
• By
Companies with significant exposure to Medicare and Medicaid have fewer options for passing along higher costs to consumers because of price controls in the programs.
• By
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
• By
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
More from Market Access
• By
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
• By
The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.
• By
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.